Robert Ryan Meyerhoff1, Chi-Fu Jeffrey Yang2, Paul J Speicher2, Brian C Gulack2, Matthew G Hartwig2, Thomas A D'Amico2, David H Harpole2, Mark F Berry3. 1. Division of Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina; Department of Immunology, Duke University, Durham, North Carolina. 2. Division of Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina. 3. Division of Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina; Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, California. Electronic address: berry037@stanford.edu.
Abstract
BACKGROUND: This study was conducted to determine how malignant pleural mesothelioma (MPM) histology was associated with the use of surgery and survival. METHODS: Overall survival of patients with stage I-III epithelioid, sarcomatoid, and biphasic MPM in the Surveillance, Epidemiology, and End Results database from 2004-2010 was evaluated using multivariate Cox proportional hazards models. RESULTS: Of 1183 patients who met inclusion criteria, histologic subtype was epithelioid in 811 patients (69%), biphasic in 148 patients (12%), and sarcomatoid in 224 patients (19%). Median survival was 14 mo in the epithelioid group, 10 mo in the biphasic group, and 4 mo in the sarcomatoid group (P < 0.01). Cancer-directed surgery was used more often in patients with epithelioid (37%, 299/811) and biphasic (44%, 65/148) histologies as compared with patients with sarcomatoid histology (26%, 58/224; P < 0.01). Among patients who underwent surgery, median survival was 19 mo in the epithelioid group, 12 mo in the biphasic group, and 4 mo in the sarcomatoid group (P < 0.01). In multivariate analysis, surgery was associated with improved survival in the epithelioid group (hazard ratio [HR] 0.72; P < 0.01) but not in biphasic (HR 0.73; P = 0.19) or sarcomatoid (HR 0.79; P = 0.18) groups. CONCLUSIONS: Cancer-directed surgery is associated with significantly improved survival for MPM patients with epithelioid histology, but patients with sarcomatoid and biphasic histologies have poor prognoses that may not be favored by operative treatment. The specific histology should be identified before treatment, so that surgery can be offered to patients with epithelioid histology, as these patients are most likely to benefit.
BACKGROUND: This study was conducted to determine how malignant pleural mesothelioma (MPM) histology was associated with the use of surgery and survival. METHODS: Overall survival of patients with stage I-III epithelioid, sarcomatoid, and biphasic MPM in the Surveillance, Epidemiology, and End Results database from 2004-2010 was evaluated using multivariate Cox proportional hazards models. RESULTS: Of 1183 patients who met inclusion criteria, histologic subtype was epithelioid in 811 patients (69%), biphasic in 148 patients (12%), and sarcomatoid in 224 patients (19%). Median survival was 14 mo in the epithelioid group, 10 mo in the biphasic group, and 4 mo in the sarcomatoid group (P < 0.01). Cancer-directed surgery was used more often in patients with epithelioid (37%, 299/811) and biphasic (44%, 65/148) histologies as compared with patients with sarcomatoid histology (26%, 58/224; P < 0.01). Among patients who underwent surgery, median survival was 19 mo in the epithelioid group, 12 mo in the biphasic group, and 4 mo in the sarcomatoid group (P < 0.01). In multivariate analysis, surgery was associated with improved survival in the epithelioid group (hazard ratio [HR] 0.72; P < 0.01) but not in biphasic (HR 0.73; P = 0.19) or sarcomatoid (HR 0.79; P = 0.18) groups. CONCLUSIONS:Cancer-directed surgery is associated with significantly improved survival for MPM patients with epithelioid histology, but patients with sarcomatoid and biphasic histologies have poor prognoses that may not be favored by operative treatment. The specific histology should be identified before treatment, so that surgery can be offered to patients with epithelioid histology, as these patients are most likely to benefit.
Authors: Walter Weder; Rolf A Stahel; Paul Baas; Urania Dafni; Marc de Perrot; Brian C McCaughan; Takashi Nakano; Harvey I Pass; Bruce W S Robinson; Valerie W Rusch; David J Sugarbaker; Nico van Zandwijk Journal: Lancet Oncol Date: 2011-11 Impact factor: 41.316
Authors: Apostolos Nakas; Edward Black; James Entwisle; Salli Muller; David A Waller Journal: Eur J Cardiothorac Surg Date: 2010-02-06 Impact factor: 4.191
Authors: N Sarhill; F Mahmoud; D Walsh; K A Nelson; S Komurcu; M Davis; S LeGrand; O Abdullah; L Rybicki Journal: Support Care Cancer Date: 2003-08-15 Impact factor: 3.603
Authors: Ilir Hysi; Françoise Le Pimpec-Barthes; Marco Alifano; Nicolas Venissac; Jérôme Mouroux; Jean-François Regnard; Marc Riquet; Henri Porte Journal: Oncol Rep Date: 2013-10-18 Impact factor: 3.906
Authors: Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2008-02-14 Impact factor: 5.209
Authors: Chi-Fu Jeffrey Yang; Brandon W Yan; Robert Ryan Meyerhoff; Shakir M Saud; Brian C Gulack; Paul J Speicher; Matthew G Hartwig; Thomas A D'Amico; David H Harpole; Mark F Berry Journal: Clin Lung Cancer Date: 2016-03-17 Impact factor: 4.785
Authors: Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass Journal: CA Cancer J Clin Date: 2019-07-08 Impact factor: 508.702
Authors: Lucian R Chirieac; Yin P Hung; Wai Chin Foo; Matthias D Hofer; Paul A VanderLaan; William G Richards; David J Sugarbaker; Raphael Bueno Journal: Cancer Date: 2019-08-07 Impact factor: 6.860
Authors: Joseph S Friedberg; Charles B Simone; Melissa J Culligan; Andrew R Barsky; Abigail Doucette; Sally McNulty; Stephen M Hahn; Evan Alley; Daniel H Sterman; Eli Glatstein; Keith A Cengel Journal: Ann Thorac Surg Date: 2016-11-05 Impact factor: 4.330
Authors: Joanna G Escalon; Kate A Harrington; Andrew J Plodkowski; Junting Zheng; Marinela Capanu; Marjorie G Zauderer; Valerie W Rusch; Michelle S Ginsberg Journal: J Comput Assist Tomogr Date: 2018 Jul/Aug Impact factor: 1.826